Copyright
©2013 Baishideng. All rights reserved.
World J Meta-Anal. May 26, 2013; 1(1): 8-9
Published online May 26, 2013. doi: 10.13105/wjma.v1.i1.8
Published online May 26, 2013. doi: 10.13105/wjma.v1.i1.8
Sirturo (Bedaquiline): The first new anti tubercular drug in decades
Krishna Undela, Department of Pharmacy Practice, JSS College of Pharmacy, JSS University, Sri Shivarathreeshwara Nagar, Mysore 570015, Karnataka, India
Author contributions: Undela K drafted the protocol, did the literature search and wrote the manuscript.
Correspondence to: Mr. Krishna Undela, Department of Pharmacy Practice, JSS College of Pharmacy, JSS University, Sri Shivarathreeshwara Nagar, Mysore 570015, Karnataka, India. krishnaundela@gmail.com
Telephone: +91-998-6779870 Fax: +91-821-2548359
Received: January 30, 2013
Revised: February 22, 2013
Accepted: March 6, 2013
Published online: May 26, 2013
Processing time: 113 Days and 18 Hours
Revised: February 22, 2013
Accepted: March 6, 2013
Published online: May 26, 2013
Processing time: 113 Days and 18 Hours
Core Tip
Core tip: The US Food and Drug Administration granted accelerated approval to Janseen Therapeutics “Sirturo (Bedaquiline)”, a diarylquinoline anti mycobacterial drug on December 28, 2012 as part of combination therapy in adults (≥ 18 years) to treat multidrug resistant tuberculosis when other alternatives are not available.